Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000254
Chunk: 40

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 40
---
 cancer.

The foundational architecture of
Renovaro Cube’s AI technology is engineered to facilitate comprehensive pan-cancer analysis through its extensive record of informative
biomarkers discovered across a diverse array of cancer types. This comprehensive repository empowers Renovaro Cube’s AI technology
to swiftly cross-reference biomarkers and explore molecular commonalities and distinctions that span multiple tumor categories.

For example, the capabilities of
Renovaro Cube’s AI technology have unearthed biomarkers capable of pinpointing a specific subgroup of thyroid cancer patients characterized
by a distinct genomic alteration, the neurotrophic tyrosine receptor kinase (“NTRK”) gene fusion. Identification of these
NTRK-positive patients provides an actionable therapeutic target.

Uses of Renovaro Cube’s AI Technology

Renovaro Cube has developed its AI platform to support:

| ● | AI-assisted patient diagnostics; |

| ● | multi-omic data analysis; |

| ● | genome-wide or targeted analysis; |

| ● | pan-cancer analysis; |

| ● | different technology platforms (sequence or array); |

| ● | tracking of each sample; |

| ● | AI-guided biomarker discovery for single or multiple cancer types; and |

| ● | logs of analysis steps and outcomes (data preparation, discovery, validation). |

Renovaro Cube’s AI platform
is an enterprise software platform that is distinguished from its competitors’ technology by its core attributes encompassing AI-guided
analysis and meticulous record-keeping of data handling procedures within audit trails, logs, and data discoveries. Renovaro Cube designed
this technology to support and validate every phase of the process, from the initial handling of raw data to the creation of essential
biomarker panels. Renovaro Cube’s AI platform also facilitates the integration of data originating from diverse sources, including
public databases and collaborative partnership data.

<div align='center'>25</div>

Illustrated below is the three-phase
workflow behind Renovaro Cube’s AI platform for biomarker discovery using DNA methylation data. This workflow commences with the
identification of pertinent single- and multi-omic data best suited to address the specific inquiries of Renovaro Cube’s clients,
and the subsequent stages involve the meticulous pre-processing and loading of this data into the platform. This process culminates in
the availability of a dashboard offering the client insights into the data’s characteristics, such as data quality, the technology
employed, and associated metadata.

| ● | Phase I of the workflow behind Renovaro Cube